fetching data ...
version:
1.02
Home
Search:
Free Text Search
List:
Abstract Titles
Sessions
Authors
Keywords
Bookmarks
Include in search:
all years
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
List: Authors
Go!
Years:
2025 (Barcelona, Spain)
Total Number of items found:
14470
in
1447
pages.
Goto page:
10
50
100
Jump to page containing Authors starting with :
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Authors
[1]
(Lliga Reumatològica Catalana), R.
2025
2025 OP0233-PARE
UNDERSTANDING SEXUALITY IN RHEUMATIC AND MUSCULOSKELETAL DISEASES: EXPANDING THE REUMASUTRA PROJECT TO THE GENERAL POPULATION
,
J. B. J. B. Negrón, R. (Lliga Reumatològica Catalana)
[1]
Aabakken, L.
2025
2025 ABS0282
INCREASED COLLAGEN DEPOSITION AND ALTERED IMMUNE CELL PROFILES ARE PRESENT IN EARLY AND LATE-STAGE SYSTEMIC SCLEROSIS WITH GASTROINTESTINAL INVOLVEMENT
,
L. Much, E. Pachera, H. Fretheim, A. Laimbacher, K. E. Lundin, L. Aabakken, L. Li, A. Hofman, P. Bearzi, M. Scharl, Ø. Molberg, O. Distler, A. M. Hoffmann-Vold
[4]
Aaløkken, T. M.
2025
2025 ABS0838
IMPROVING EARLY ILD DETECTION IN SJÖGREN DISEASE: A RISK ESTIMATION TOOL FOR CLINICAL PRACTICE
,
A. M. Hoffmann-Vold, K. Kastrati, M. Sprecher, E. Langballe, P. P. Diep, H. Fretheim, H. Andersson, P. Studenic, B. Müller-Durovic, C. Brunborg, D. C. Bruni, C. Clarenbach, T. Frauenfelder, T. M. Aaløkken, N. Moe, H. Prosch, Ø. Molberg, O. Distler
2025 ABS0899
UNRAVELING THE DIVERSE TREATMENT LANDSCAPE FOR PATIENTS WITH INTERSTITIAL LUNG DISEASE IN SJÖGREN’S DISEASE
,
K. Kastrati, M. Sprecher, E. Langballe, P. P. Diep, H. Fretheim, H. Andersson, P. Studenic, D. Aletaha, L. T. Göthans, K. Anderle, B. Müller, C. Brunborg, D. C. Bruni, C. Clarenbach, T. Frauenfelder, T. M. Aaløkken, N. Moe, H. Prosch, Ø. Molberg, O. Distler, H. Lechner-Radner, A. M. Hoffmann-Vold
2025 OP0044
Interstitial lung disease associated with Sjögren’s disease (SjD-ILD) is frequently progressive across all high-resolution computed tomography (HRCT) patterns
,
M. Sprecher, K. Kastrati, D. C. Bruni, B. Müller-Durovic, T. Frauenfelder, C. Clarenbach, E. Langballe, H. Fretheim, N. Moe, H. Andersson, P. P. Diep, Ø. Molberg, C. Brunborg, T. M. Aaløkken, P. Studenic, H. Prosch, H. Lechner-Radner, O. Distler, A. M. Hoffmann-Vold
2025 OP0084
Annual HRCT monitoring is key to early detection of ILD progression and improved survival in SSc
,
A. M. Hoffmann-Vold, L. Petelytska, H. Fretheim, T. M. Aaløkken, M. O. Becker, H. J. Bjørkekjær, C. Brunborg, D. C. Bruni, C. Clarenbach, P. P. Diep, R. Dobrota, M. T. Durheim, M. Elhai, T. Frauenfelder, E. Langballe, Ø. Midtvedt, N. Moe, C. Mihai, A. C. Sarbu, M. Sprecher, Ø. Molberg, O. Distler
[1]
Aanesen, F.
2025
2025 POS1198
REMONIT GOUT FEASIBILITY STUDY: A SELF-MANAGEMENT APP IN A TREAT-TO-TARGET GOUT CARE APPROACH
,
J. Stjärne, F. Aanesen, S. Søhus, H. B. Hammer, T. Uhlig, E. Kristianslund, A. T. Tveter, N. Dalbeth, A. Abhishek, I. J. Berg, N. Osteras
[1]
Aaramaa, H. K.
2025
2025 POS0068
POLYGENIC RISK SCORES IMPROVE RISK ASSESSMENT OF CARDIOMETABOLIC COMORBIDITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS
,
H. K. Aaramaa, P. Isomäki, A. Kerola, A. Palomäki, K. Eklund, F. N/A, N. Mars
[1]
Aarntzen, E.
2025
2025 OP0014
CD4+ TRAIL+ T Cells with Interferon-Stimulated Gene signature Differentially Restrict Anti-Nuclear Antigen Responses in M. Sjögren and Systemic Sclerosis
,
T. I. Papadimitriou, P. Singh, A van Caam, M. Vonk, I. J. M. de Vries, P van der Kraan, R. Smeets, M. Koenders, E. Aarntzen, H. Koenen, M. Huijnen, R. M. Thurlings
[15]
Aarrestad Provan, S.
2025
2025 ABS0645
TREATMENT PATTERNS AND DETERMINANTS OF DMARD SWITCHING IN EUROPEAN RHEUMATOID ARTHRITIS COHORTS: A MULTI-NATIONAL ANALYSIS
,
D. Di Giuseppe, N. Steinz, J. Sexton, C. A. Hana, H. Lechner-Radner, D. Sieghart, S. Aarrestad Provan, R. Knevel, J. Askling
2025 ABS1116
HOW FAST CAN YOU REACH THE SERUM URATE TARGET DURING INTENSIVE URATE LOWERING THERAPY IN GOUT
,
T. Uhlig, L. F. Karoliussen, J. Sexton, S. Aarrestad Provan, E. A. Haavardsholm, H. B. Hammer
2025 OP0177
EXPLORING DEFINITIONS AND PREVALENCE OF DIFFICULT-TO-TREAT PSORIATIC ARTHRITIS IN 13,872 PATIENTS FROM FIVE NORDIC REGISTRIES
,
L. M. Nielung, D. Di Giuseppe, M. Lund Hetland, J. Askling, D. Nordström, S. Aarrestad Provan, B. Gudbjornsson, Ó. Pálsson, L. Dreyer, B. Michelsen, B. Delcoigne, K. Chatzidionysiou, J. K. Wallman, B. Glintborg
2025 OP0183
CANCER MORTALITY IN FEMALE ARTHRITIS PATIENTS: 20 YEARS FOLLOW-UP FROM THE PROSPECTIVE NOR-DMARD STUDY
,
H. S. Ørbo, S. Fukui, L. M. Sundbakk, S. K. Tedeschi, T. K. Kvien, G. L. Goll, D. H. Solomon, S. Aarrestad Provan
2025 OP0192
ADD-ON VS. REPLACEMENT csDMARD STRATEGIES POST-METHOTREXATE: A EUROPEAN ANALYSIS ON CSDMARD TREATMENT CHOICES
,
N. Steinz, D. Di Giuseppe, T. D. Maarseveen, C. A. Hana, J. Sexton, C. Popescu, C. Mogosan, C. Codreanu, S. Aarrestad Provan, H. Lechner-Radner, D. Sieghart, J. Askling, R. Knevel
2025 OP0232
CANCER INCIDENCE AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY)
,
R. Aymon, D. Mongin, B. Gilbert, R. Guemara, D. Choquette, C. Codreanu, L. Coupal, I. Flouri, R. Fritsch-Stork, R. Giacomelli, D. Huschek, F. Iannone, T. K. Kvien, L. Otero-Varela, D. Nordström, K. Pavelka, M. Pombo-Suarez, S. Aarrestad Provan, Z. Rotar, P. Sidiropoulos, E. Vieira-Sousa, A. Strangfeld, J. Závada, D. S. Courvoisier, A. Finckh, K. Lauper
2025 POS0150
EVOLUTION OF JANUS KINASE INHIBITORS (JAKi) PRESCRIPTIONS SINCE 2015 IN AN INTERNATIONAL COLLABORATION OF RHEUMATOID ARTHRITIS REGISTERS (THE ‘JAK-pot’ STUDY): EFFECT OF REGULATORY WARNINGS
,
D. Mongin, R. Aymon, D. Choquette, L. Coupal, C. Codreanu, F. Iannone, S. Aarrestad Provan, R. Fritsch-Stork, T. K. Kvien, D. Nordström, K. Pavelka, J. Závada, M. Pombo-Suarez, L. Otero-Varela, E. Vieira-Sousa, Z. Rotar, P. Sidiropoulos, A. Bertsias, D. S. Courvoisier, A. Finckh, K. Lauper, O. Elkayam, V. Furer
2025 POS0155
CHOICE AND EFFECTIVENESS OF SECOND DMARDS AFTER MTX: COMPARING BIOLOGICAL, TARGETED, AND CONVENTIONAL OPTIONS IN EUROPEAN RA COHORTS
,
D. Di Giuseppe, N. Steinz, J. Sexton, C. A. Hana, H. Lechner-Radner, D. Sieghart, S. Aarrestad Provan, R. Knevel, J. Askling
2025 POS0363-PARE
EXPLORING THE PERCEPTIONS OF THE WORK OF PATIENT RESEARCH PARTNERS: THE iPREPARE STUDY
,
M. J. Stevens, M. de Wit, P. Böhm, L. Carmona, M. Elhai, R. J. O. Ferreira, I. de Groot, I. Kjeken, S. Makri, R. Parr, E. Petersson, S. Aarrestad Provan, J. Skandsen, T. Snell, G. J. Macfarlane, R. Hollick
2025 POS0585
SEX DIFFERENCES IN THE SAFETY PROFILE OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS: RESULTS FROM THE JAK-POT INTERNATIONAL COLLABORATION
,
L. Otero-Varela, C. Sánchez-Piedra, R. Aymon, D. Mongin, B. Gilbert, R. Guemara, D. Choquette, C. Codreanu, L. Coupal, R. Fritsch-Stork, R. Giacomelli, D. Huschek, K. Hyrich, F. Iannone, T. K. Kvien, D. Nordström, K. Pavelka, M. Pombo-Suarez, S. Aarrestad Provan, Z. Rotar, P. Sidiropoulos, E. Vieira-Sousa, A. Strangfeld, N. Trokovic, J. Závada, S. S. Zhao, D. S. Courvoisier, A. Finckh, K. Lauper
2025 POS0752
RAPID EFFECTIVENESS OF JAK-INHIBITORS, BIOLOGICS, AND CONCOMITANT GLUCOCORTICOID DURING THE FIRST MONTHS. AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE JAK-POT STUDY)
,
D. S. Courvoisier, M. Jarlborg, D. Mongin, R. Aymon, R. F. Caporali, D. Choquette, C. Codreanu, L. Coupal, D. Huschek, K. Hyrich, F. Iannone, T. K. Kvien, R. Fritsch-Stork, D. Nordström, N. Trokovic, L. Otero-Varela, K. Pavelka, S. Aarrestad Provan, A. M. Rodrigues, Z. Rotar, P. Sidiropoulos, A. Strangfeld, J. Závada, S. S. Zhao, A. Finckh, K. Lauper
2025 POS1077
Cost-effectiveness of proactive terapeutic drug monitoring (TDM) in patients with inflmmatory disease-results from the Nor-Drum trial
,
T. Holly, M. K. Brun, K. K. Jørgensen, G. L. Goll, J. Sexton, J. E. Gehin, T. K. Kvien, J. Jahnsen, S. Aarrestad Provan, N. Bolstad, E. Aas, E. A. Haavardsholm, I. Kristiansen, S. W. Syversen, G. Hagen
2025 POS1154
IMPACT OF PRIOR TNF INHIBITOR TREATMENT ON THE TIME TO ACHIEVE LOW DISEASE ACTIVITY AND THE DURATION OF LOW DISEASE ACTIVITY IN 17,858 EUROPEAN PATIENTS WITH AXIAL SPONDYLOARTHRITIS INITIATING A TNF INHIBITOR OR AN IL-17A INHIBITOR
,
J. Heberg, S. Georgiadis, M. Pons, A. G. Loft, B. Michelsen, L. Linde, D. Di Giuseppe, S. H. Rasmussen, M. Shoae Kazemi, G. J. Macfarlane, G. T. Jones, K. Laas, S. Vorobjov, I. Castrejon, F. Sánchez-Alonso, Z. Rotar, K. P. Pirkmajer, L. Šenolt, J. Baranová, B. Glintborg, A. Ciurea, M. Bernardes, P. Valente, B. Gudbjornsson, G. Grondal, G. Bakland, C. Codreanu, C. Mogosan, S. Aarrestad Provan, F. Iannone, R. F. Caporali, J. K. Wallman, V. Rantalaiho, R. Peltomaa, K. Pavelka, P. Horak, D. Esperança Almeida, S. Dias Rodrigues, L. Midtbøll Ørnbjerg, M. Østergaard, M. Lund Hetland
2025 POS1250
ASSOCIATION BETWEEN METABOLIC COMORBIDITIES AND RETENTION RATES OF FIRST-LINE b/tsDMARD TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS: EUROPEAN REAL-WORLD RESULTS
,
Z. Faizy Ahmadzay, L. Midtbøll Ørnbjerg, M. Østergaard, J. Jørgensen, J. Heberg, A. G. Loft, B. Michelsen, G. T. Jones, P. Hellamand, S. Møller-Bisgaard, K. Y. Jensen, M. Shoae Kazemi, P. Karimi Reikandeh, J. Závada, M. Bernardes, E. Vieira-Sousa, I. Castrejon, L. Otero-Varela, C. Codreanu, L. Kuusalo, V. Rantalaiho, A. Regierer, A. Reich, B. Moeller, R. Micheroli, T. K. Kvien, S. Aarrestad Provan, K. Laas, S. Vorobjov, Z. Rotar, K. Perdan-Pirkmajer, F. Iannone, F. Conti, B. Gudbjornsson, D. Di Giuseppe, M. G. H. van de Sande, H. Yarkan-Tuğsal, M. Lund Hetland, B. Glintborg
2025 POS1515-HPR
TREATING GOUT TO TARGET SERUM URATE IMPROVES HEALTH-RELATED QUALITY OF LIFE AND UTILITY OVER FIVE YEARS
,
G. Hagen, L. F. Karoliussen, J. Sexton, E. A. Haavardsholm, S. Aarrestad Provan, H. Hammer, T. Uhlig
[1]
Aas, E.
2025
2025 POS1077
Cost-effectiveness of proactive terapeutic drug monitoring (TDM) in patients with inflmmatory disease-results from the Nor-Drum trial
,
T. Holly, M. K. Brun, K. K. Jørgensen, G. L. Goll, J. Sexton, J. E. Gehin, T. K. Kvien, J. Jahnsen, S. Aarrestad Provan, N. Bolstad, E. Aas, E. A. Haavardsholm, I. Kristiansen, S. W. Syversen, G. Hagen
[1]
Abaab, T.
2025
2025 ABS0287
DISTINCT STABILITY AND SUPPRESSIVE PHENOTYPE OF SYNOVIAL VERSUS PERIPHERAL TREG IN RHEUMATOID ARTHRITIS
,
T. Abaab, J. Sigaux, L. Semerano, M. C. Boissier, J. Biton, N. Bessis
[7]
Abacar, K.
2025
2025 ABS0728
THE CLINICAL CHARACTERISTICS AND 2-YEAR FOLLOW-UP OF TAKAYASU ARTERITIS PATIENTS WITH PULMONARY ARTERY INVOLVEMENT
,
G. Sevik, K. Abacar, A. Avcu, D. Kocakaya, F. Baltacioglu, H. Direskeneli, F. Alibaz- Oner
2025 ABS0910
DEVELOPMENT OF A DEEP LEARNING-BASED ARTIFICIAL INTELLIGENCE TOOL FOR AUTOMATED mSASSS CALCULATION IN ANKYLOSING SPONDYLITIS
,
K. Abacar, Ş. Çolakoğlu Özkaya, E. Biyikli, O. Buğdayci, A. Denizli, B. Koçak, M. B. Çöteli, D. Akdoğan, A. Gökduman, P. Atagündüz
2025 POS0027
First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care
,
T. Toyoda, K. Abacar, F. Shuweihdi, M. Sheridan, J. Nam, A. L. Tan, L. A. Bissell, P. Emery, K. Mankia
2025 POS0126
TWO DISTINCT PATTERNS OF SACROILIAC JOINT BONE MARROW OEDEMA IN AXIAL SPONDYLOARTHRITIS ARE ASSOCIATED WITH HLA-B27 STATUS, BODY MASS INDEX AND/PSORIASIS
,
K. Abacar, A. Di Matteo, G. De Marco, K. Mankia, J. Weddell, S. R. Harrison, H. Marzo-Ortega, D. McGonagle
2025 POS0472
Quantitative MRI tenosynovitis volume explains the association between tendon involvement and progression to clinical arthritis in anti-CCP+ at risk individuals
,
K. Abacar, A. Di Matteo, L. Duquenne, J. Nam, P. Emery, D. McGonagle, K. Mankia
2025 POS1196
CLINICAL FEATURES AND PHENOTYPIC SIMILARITIES OF PATIENTS WITH FAMILIAL BEHCET’S DISEASE
,
K. Abacar, A. E. Boncukcuoğlu, R. Deniz, B. C. Uludoğan, D. Kaş, E. Alkan, G. Kaya, T. Bozkurt, N. S. Yasar Bilge, C. Bes, T. Kaşifoğlu, D. McGonagle, T. Ergun, H. Direskeneli, F. Alibaz- Oner
2025 POS1299
ULTRASOUND JOINT, TENDON AND ENTHESEAL INFLAMMATION IN CANCER PATIENTS WHO DEVELOP ARTHRITIS OR ARTHRALGIA AFTER EXPOSURE TO IMMUNE CHECKPOINT INHIBITORS: RESULTS OF A MULTI-NATIONAL COHORT STUDY
,
A. Di Matteo, K. Harnden, S. Sharrack, K. Abacar, L. Di Geso, R. Horvath, J. Hurnakova, T. Okano, D. Sahin Eroglu, P. V. Voulgari, J. J. de Agustin, E. Filippucci, P. Emery, K. Mankia
Goto page:
10
50
100